Evaluation of medical prescriptions and off-label use on board ships to improve healthcare quality

被引:0
|
作者
Nittari, G. [1 ]
Pallotta, G. [1 ]
Pirillo, I. [1 ]
Ricci, G. [2 ]
Amenta, F. [1 ,3 ]
机构
[1] Univ Camerino, Telemed & Telepharm Ctr, Camerino, Italy
[2] Univ Camerino, Legal Med Sect, Sch Law, Camerino, Italy
[3] Int Radiomed Ctr CIRM, Res Dept, Rome, Italy
关键词
Prescriptions; Off-label; Ships; Health quality; ETHICS COMMITTEES; ASSISTANCE; SEA;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: This study analyzed the appropriateness of drug therapies prescribed for a particular category of patients: the seafarers. We investigated an important problem of this area: the off-label use of drugs, which resulted to be a consequence of major shortcomings in the on-board pharmacies of ships. The off-label use of drugs is allowed. but can lead to some not negligible ethical and health problems. compromising the quality of provided healthcare. MATERIALS AND METHODS: The analysis was performed on electronic health records of patients onboard ships without physicians, and assisted by the CIRM from 2011 to 2015. This work is divided into two phases: in the first one. we classified the diagnoses registered onboard on the basis of the ICD-10 classification proposed by the WHO. In the second phase, we evaluated the congruence of the pharmacological therapies prescribed by CIRM physicians, according to the MICROMEDEX Database, which provides comprehensive information about drugs and their use. RESULTS: From the analysis emerged that prescribed drugs were not always corresponded to their primary indication of use. In particular, in 2011 off-label drug use was widely spread (more than 30%) in some ICD-10 classes. In the following years (2012-2015) a decrease of off-label use of drugs was noticed. CONCLUSIONS: The results suggest that a standardization of onboard pharmacies is crucial. in order to have a complete on-board pharmacy that will allow preventing and counteracting any situation of health danger, which may occur onboard, ensuring high quality healthcare to seafarers all over the world.
引用
收藏
页码:4392 / 4400
页数:9
相关论文
共 50 条
  • [21] The prevalence and consequences of support for off-label Ozempic prescriptions
    Callaghan, Timothy
    Motta, Matthew
    Stein, Michael
    Goidel, Kirby
    HEALTH ECONOMICS POLICY AND LAW, 2025,
  • [23] Cardiovascular drugs and off-label prescriptions in a paediatric population
    Rocca, M.
    Rousseau, V.
    Montastruc, J. L.
    Durrieu, G.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2015, 29 : 31 - 31
  • [24] Utilisation and Off-Label Prescriptions of Respiratory Drugs in Children
    Schmiedl, Sven
    Fischer, Rainald
    Ibanez, Luisa
    Fortuny, Joan
    Klungel, Olaf H.
    Reynolds, Robert
    Gerlach, Roman
    Tauscher, Martin
    Thuermann, Petra
    Hasford, Joerg
    Rottenkolber, Marietta
    PLOS ONE, 2014, 9 (09):
  • [25] Off-label prescriptions in Internal Medicine: difficulties involved
    Gambetti, S.
    Lupattelli, A.
    Ventura, S.
    ITALIAN JOURNAL OF MEDICINE, 2007, 1 (03) : 69 - 75
  • [26] Off-label prescriptions: are we really so inhibited?
    Scanelli, G.
    ITALIAN JOURNAL OF MEDICINE, 2007, 1 (03) : 5 - 6
  • [27] Off-label drug prescriptions on the rise among physicians
    不详
    COMPENDIUM ON CONTINUING EDUCATION FOR THE PRACTICING VETERINARIAN, 2006, 28 (07): : 491 - 491
  • [28] The off-label prescriptions Authorisation on the Market in children and adolescents
    Venel, V.
    Petron-Bardou, C.
    EUROPEAN PSYCHIATRY, 2013, 28 (08) : 92 - 92
  • [29] Off-Label Prescriptions in Italian Hospices: A National Survey
    Toscani, Franco
    Di Giulio, Paola
    Campi, Rita
    Pellerin, Ivanoe
    De Luca, Anna
    Casale, Giuseppe
    JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2009, 38 (03) : 365 - 371
  • [30] Factors Associated With Off-Label Oncology Prescriptions: The Role of Cost and Financing in a Universal Healthcare System
    Gordon, Noa
    Goldstein, Daniel A.
    Tadmor, Boaz
    Stemmer, Salomon M.
    Greenberg, Dan
    FRONTIERS IN PHARMACOLOGY, 2021, 12